Search results for "Portal"

showing 10 items of 336 documents

Natural history of congestive gastropathy in cirrhosis

1990

In a prospective study of the natural history of congestive gastropathy, 212 consecutive cirrhotic patients (75 treated with sclerotherapy) were included. Mean follow-up was 46 months. Mild gastropathy (mosaiclike pattern) was found in 110 patients and severe gastropathy (granular mucosa with cherry spots) was found in 20. Prevalence of Helicobacter pylori, formerly Campylobacter pylori, was 50% in patients without, 43% in those with mild, and 28% in those with severe gastropathy. Congestive gastropathy was significantly more frequent in patients treated with sclerotherapy (83% vs. 50%, P less than 10(-5)). Sixty-month actuarial proportions of patients free of anemia (in the absence of hema…

medicine.medical_specialtyCirrhosisHepatologyAnemiabusiness.industrymedicine.medical_treatmentGastroenterologyPortal hypertensive gastropathymedicine.diseaseGastroenterologyEsophageal varicesMelenaInternal medicinemedicineSclerotherapymedicine.symptomVaricesComplicationbusinessGastroenterology
researchProduct

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cir…

2012

Summary.  Genetic factors can influence the outcome of antiviral therapy in chronic hepatitis C (HCV). We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-Interferon and ribavirin. A prospective cohort of 233 patients with compensated cirrhosis received 1–1.5 μg/kg/week of Peg-Interferon alpha-2b plus 1000–1200 mg/day of RBV for 48 weeks. A sustained virologic response (SVR) was achieved in 27% of patients. On multivariate logistic analysis, the absence of oesophageal varices (OR 3.64 CI 95% 1.27–10.44 P = 0.016), infection with genotype 2 or 3 (OR 4.06, CI 95% 1.08–15.26, P = 0.038…

medicine.medical_specialtyCirrhosisHepatologyCombination therapybusiness.industryRibavirinmedicine.diseaseGastroenterologychemistry.chemical_compoundInfectious DiseaseschemistryVirologyInternal medicineImmunologymedicinePortal hypertensionITPAVaricesRapid Virologic ResponsebusinessProspective cohort studyJournal of Viral Hepatitis
researchProduct

Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems

2008

Summary Background  A major problem in assessing the likelihood of survival of patients with hepatocellular carcinoma (HCC) arises from a lack of models capable of predicting outcome accurately. Aim  To compare the ability of the Italian score (CLIP), the French classification (GRETCH) and the Barcelona (BCLC) staging system in predicting survival in patients with HCC. Methods  We included 406 consecutive patients with cirrhosis and HCC. Seventy-eight per cent of patients had hepatitis C. Independent predictors of survival were identified using the Cox model. Results  One-hundred and seventy-eight patients were treated, while 228 were untreated. The observed mortality was 60.1% in treated p…

medicine.medical_specialtyCirrhosisHepatologyPerformance statusbusiness.industryProportional hazards modelGastroenterologymedicine.diseaseGastroenterologyPortal vein thrombosisInternal medicineHepatocellular carcinomamedicineCarcinomaPharmacology (medical)businessLiver cancerSurvival rateAlimentary Pharmacology & Therapeutics
researchProduct

Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation

2012

Background and Aims:  Current histological scoring systems do not subclassify cirrhosis. Computer-assisted digital image analysis (DIA) of Sirius Red-stained sections measures fibrosis morphologically producing a fibrosis ratio (collagen proportionate area [CPA]). CPA could have prognostic value within a disease stage, such as cirrhosis. The aim of the present study was to evaluate CPA in patients with recurrent hepatitis C virus (HCV) allograft cirrhosis and assess its relationship with hepatic venous pressure gradient (HVPG). Methods:  In 121 consecutively-transplanted HCV patients with HVPG, measured contemporaneously with transjugular liver biopsies, 65 had Ishak stage 5 or 6 disease (4…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryPortal venous pressuremedicine.medical_treatmentGastroenterologyHepatitis CLiver transplantationmedicine.diseaseGastroenterologychemistry.chemical_compoundchemistryInterquartile rangeInternal medicinecardiovascular systemmedicinePortal hypertensionheterocyclic compoundsDecompensationbusinessSirius RedJournal of Gastroenterology and Hepatology
researchProduct

The stomach in liver cirrhosis

1991

Abstract The stomachs of cirrhotic patients are frequently subject to a number of alterations, detectable by endoscopy, the presence of which indicates a disturbance in the mucosa. Several investigators believe that portal hypertension plays an etiopathogenetic role. Three groups of subjects were studied prospectively: 83 cirrhotic patients with portal hypertension, 53 cirrhotic patients without portal hypertension, and 135 control subjects. Snake skin, scarlatina rash, and petechia were the most frequent endoscopic findings in the cirrhotic patients with portal hypertension ( P

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryEsophagogastroduodenoscopyStomachGastroenterologymedicine.diseaseControl subjectsGastroenterologyRashEndoscopymedicine.anatomical_structureInternal medicineMedicinePortal hypertensionmedicine.symptomPetechiabusinessGastroenterology
researchProduct

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

2012

BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was pre…

medicine.medical_specialtyCirrhosisIntention-to-treat analysisHepatologybusiness.industrycirrhosisGastroenterologyPortal vein trombosis; Enoxaparin; cirrhosisenoxaparin cirrhosis portal thrombosismedicine.diseasePortal vein trombosisSurgeryPortal vein thrombosislaw.inventionSpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseRandomized controlled triallawHepatocellular carcinomaMedicinePortal hypertensionEnoxaparinbusinessGastroenterology
researchProduct

Duplexsonographische Untersuchungen zur Pathogenese der lienalen Hämodynamik bei Leberzirrhose

2008

AIM OF STUDY The haemodynamic role of the spleen in portal hypertension remains unclear. Duplex sonography was undertaken prospectively to discover the relationship of splenomegaly and splenic vein flow to type and severity of liver cirrhosis and portal vein flow, as well as to the degree of oesophageal varices. PATIENTS AND METHODS 89 patients (54 men, 35 women; mean age 52 [26-81] years), diagnosed in the second half of 1993 as having liver cirrhosis were consecutively included in the study. In 40 patients the cirrhosis was in stage A (according to Child-Pugh classification), in 31 in stage B and in 18 in stage C. RESULTS Portal vein flow fell significantly with increasing degree of cirrh…

medicine.medical_specialtyCirrhosisbusiness.industryHemodynamicsSpleenGeneral Medicinemedicine.diseaseGastroenterologyPathophysiologymedicine.anatomical_structureSplenic veinInternal medicinemedicinePortal hypertensionStage (cooking)VaricesbusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

The Clinical Course of Portal Hypertension in Liver Cirrhosis

2000

Portal hypertension is caused by liver cirrhosis in almost %% of patients in Europe and in North America. Other causes such as hepato-splenic schistosomiasis, noncirrhotic portal fibrosis and extrahepatic portal vein thrombosis are more common in Asia and South America.

medicine.medical_specialtyCirrhosisbusiness.industryPortal venous pressurePortal hypertensive gastropathySchistosomiasismedicine.diseaseGastroenterologyPortal vein thrombosisEsophageal varicesInternal medicinePortal fibrosismedicinePortal hypertensionbusiness
researchProduct

Funktionsdiagnostik vor Leberresektion - teuer und ohne klinische Relevanz?

2007

Hepatic failure after liver resection is a complication that is dreaded by surgeons and has a poor outcome. Inadequate functional reserve of the remaining liver parenchyma leads to the inability to regenerate and finally to the progression of liver failure. In order to predict the functional reserve of the remaining liver parenchyma, many different liver function tests have been established. Basis for most liver function assessments are metabolic liver functions such as cytochrome p 450 dependent pathways or the extraction and biliary excretion of dye. Nuclear imaging of the liver parenchyma does not only allow visualisation of the liver but also accumulation of information on hepatocyte vo…

medicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industrymedicine.diseaseGastroenterologyLiver diseasemedicine.anatomical_structureInternal medicineHepatocytemedicinePortal hypertensionSurgeryClinical significanceLiver functionComplicationbusinessLiver function testsZentralblatt für Chirurgie
researchProduct

Computed Tomography of HCC

2016

Contrast-enhanced CT allows an accurate noninvasive diagnosis of Hepatocellular Carcinoma (HCC) nodules, and assessment of hepatic vascular anatomy and patency. The use of state-of-the-art equipment and of a tailored protocol is crucial. CT results help to detect and stage HCC, select the best treatment option, and evaluate response to therapy. In this chapter, the CT protocol for the cirrhotic liver, the CT features of HCC before and after treatment and of portal vein thrombosis will be described.

medicine.medical_specialtyCirrhotic liverResponse to therapymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentComputed tomographymedicine.diseasedigestive system diseasesPortal vein thrombosisHepatocellular carcinomamedicineRadiologyPercutaneous ethanol injectionStage (cooking)businessAfter treatment
researchProduct